Logo Lanfrica
  • Accueil
  • Atlas
  • Analyses
  • Documentation
  • Sign in

© 2026 Lanfrica. Tous droits réservés. Tous les droits d'auteur des ressources affichées sur le site Web Lanfrica appartiennent aux détenteurs de droits d'auteur d'origine, sauf indication contraire explicite.

Growth and capacity for cost‐effectiveness analysis in Africa

Domaine:

healthcare

Type de record:

paper
Créateur:
AriJoaBriAvn
Éditeur:
WILEY
Hôte:
Abstract As economic evaluation becomes increasingly essential to support universal health coverage (UHC), we aim to understand the growth, characteristics, and quality of cost‐effectiveness analyses (CEA) conducted for Africa and to assess institutional capacity and relationship patterns among authors. We searched the Tufts Medical Center CEA Registries and four databases to identify CEAs for Africa. After extracting relevant information, we examined study characteristics, cost‐effectiveness ratios, individual and institutional contribution to the literature, and network dyads at the author, institution, and country levels. The 358 identified CEAs for Africa primarily focused on sub‐Saharan Africa (96%) and interventions for communicable diseases (77%). Of 2,121 intervention‐specific ratios, 8% were deemed cost‐saving, and most evaluated immunizations strategies. As 64% of studies included at least one African author, we observed widespread collaboration among international researchers and institutions. However, only 23% of first authors were affiliated with African institutions. The top producers of CEAs among African institutions are more adherent to methodological and reporting guidelines. Although economic evidence in Africa has grown substantially, the capacity for generating such evidence remains limited. Increasing the ability of regional institutions to produce high‐quality evidence and facilitate knowledge transfer among African institutions has the potential to inform prioritization decisions for designing UHC.

Visit

doi.org

Licenses

http://creativecommons.org/licenses/by/4.0/

Similaires

Cost-effectiveness analysis of malaria chemoprophylaxis for travellers to West-AfricaA Cost Effectiveness and Capacity Analysis for the Introduction of Universal Rotavirus Vaccination in Kenya: Comparison between Rotarix and RotaTeq VaccinesGrowth and capacity for cost‐effectiveness analysis in Africa النمو والقدرة على تحليل فعالية التكلفة في أفريقيا Croissance et capacité d'analyse coût-efficacité en Afrique Crecimiento y capacidad de análisis derentabilidad en ÁfricaCost-Effectiveness Analysis RBT vs FBATTime-Series Forecasting Model Evaluation for Cost-Effectiveness Analysis of Municipal Water Systems in South Africa,Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence

Cost-effectiveness analysis of malaria chemoprophylaxis for travellers to West-Africa

Abstract Background The importation of malaria to non-endemi

A Cost Effectiveness and Capacity Analysis for the Introduction of Universal Rotavirus Vaccination in Kenya: Comparison between Rotarix and RotaTeq Vaccines

Background

Diarrhoea is an important cause of death in the developing world, and rot

Growth and capacity for cost‐effectiveness analysis in Africa النمو والقدرة على تحليل فعالية التكلفة في أفريقيا Croissance et capacité d'analyse coût-efficacité en Afrique Crecimiento y capacidad de análisis derentabilidad en África

Abstract As economic evaluation becomes increasingly essential to support universal health coverage

Cost-Effectiveness Analysis RBT vs FBAT


A stochastic cost-effectiveness analysis built using @Risk 7.5 add-on for Microsoft Excel to cal

Time-Series Forecasting Model Evaluation for Cost-Effectiveness Analysis of Municipal Water Systems in South Africa,

Municipal water systems in South Africa have faced challenges related to cost-effectiveness

Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence

Abstract Background This study aims at evaluating the cost-effectiveness of a 2-dose schedule human